KPJ Healthcare posts RM402 million net profit in 2025

KPJ Healthcare achieved a robust financial performance in the 2025 Financial Year, with net profit climbing 10% to RM402 million and revenue increasing 9% to RM4.26 billion. This growth reflects the company's successful transition from a hospital network to an integrated health system, KPJ Health System (KPJHS).

“

This approach strengthens our ability to provide high-quality care, nurture future healthcare talent, and drive innovation, while creating sustainable value for patients, communities, and shareholders.

Tan Sri Dr. Ismail Bakar, Chairman of KPJ Healthcare, highlighted that this achievement underscores the group's commitment to high-quality care, nurturing future healthcare talent, and driving innovation. He emphasized the company's dedication to sustainable value creation for patients, communities, and shareholders, aiming for continued growth with a clear purpose and long-term impact.

President and Managing Director Chin Keat Chyuan detailed the group's focus on enhancing existing capabilities through system integration, developing Centers of Excellence (CoE), and adopting new technologies like AI and genomics. Significant clinical milestones in FY2025 included the launch of a Cardiac and Thoracic CoE and pioneering procedures such as the first private sector Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) in Malaysia.

“

Moving forward, we remain committed to ensuring KPJ continues to grow with a clear purpose, resilience, and long-term impact, thereby creating broader access to quality healthcare.

Looking ahead to FY2026, KPJ Healthcare plans to launch a Neurosains and Stroke CoE, conduct kidney transplant procedures, and sign a Memorandum of Understanding with the Royal College of Surgeons of England. As Malaysia's first private integrated academic health system, KPJ Healthcare remains committed to accelerating its digital and clinical transformation agendas to improve healthcare service delivery.

“

Throughout FY2025, KPJ Healthcare achieved various significant clinical milestones, including the launch of the Cardiac and Thoracic CoE at Johor Specialist Hospital, and the implementation of pioneering treatment procedures such as the first private sector Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) in Malaysia and Deep Brain Stimulation (DBS) surgery.